Breaking News
March 22, 2018 - Researchers explain link between 2 key Alzheimer’s proteins
March 22, 2018 - Patients on replacement therapy with thyroid hormone may have more comorbidities
March 22, 2018 - Higher online patient ratings linked to urologists who saw fewer Medicare patients
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
March 21, 2018 - Mixed Results for Shorter DAPT in ACS Patients
March 21, 2018 - Scientists discover fish scale-derived collagen effective for healing wounds
March 21, 2018 - Genomics England announces new partnership to improve efficiency of next-generation sequencing analysis
March 21, 2018 - Adjuvant AC chemotherapy found to be effective in treating HRD-positive breast cancer patients
March 21, 2018 - Researchers identify new treatment targets for lung diseases using big data
March 21, 2018 - Kids see more women in science than five decades ago
March 21, 2018 - Research shows link between chronic fatigue syndrome and lower thyroid hormone levels
March 21, 2018 - Alzheimer’s disease on the rise
March 21, 2018 - Two Agents Equal as Pretreatment for Adrenal Tumor Surgery
March 21, 2018 - ‘Icebreaker’ protein opens genome for T cell development, researchers find
March 21, 2018 - Women in medicine shout #Metoo about sexual harassment at work
March 21, 2018 - Mother’s pre-pregnancy waist size may be linked to child’s autism risk
A Patient’s Journey: And Now, a Word from a Pathologist

A Patient’s Journey: And Now, a Word from a Pathologist

image_pdfDownload PDFimage_print

I recently ran across a wide-ranging blog, “Getting More From Les,” written by suburban Chicago pathologist Lester Raff, MD.

I was amused by his tongue-in-cheek take on pathologists like him “giving (prostate) cancer” to patients. Actually, giving them prostate cancer diagnoses.

I wrote a fan note to Raff and told him there was another prostate cancer blogger in town. We started an email exchange, which I will share shortly.

We look at the pathology slide from different vantage points. Me with a Gleason 6 diagnosed by a pathologist like him. He as the expert using the art and science of pathology to diagnose cancer as lab director for UroPartners, a large urology group in the Chicago area. (He stresses in his blog and in his conversation with me that he is expressing his own opinions, not those of UroPartners.)

It turns out we had more in common. When he graduated from eighth grade, he had his eye on journalism. He wanted to attend the highly regarded Medill School of Journalism where, as it happens, I have taught in the grad school over the past 10 years.

But he took a radical turn and became a pathologist. Medicine’s gain has been journalism’s loss, though Les keeps a hand in journalism through his blog.

I had some questions from the patient point of view and solicited others from patient advocates Mike Scott, founder of Prostate Cancer International and Rick Davis, founder of Answer Cancer Foundation.

Here is my Q & A with Raff.

Wolinsky: “Do you often speak with men to whom you ‘give’ prostate cancer.”

Raff: “It is very interesting to me to see your perspective. As a pathologist I rarely talk with patients, other than friends and relatives whose biopsies I often wind up reading. I would enjoy talking with more patients, but only a few ever give me a call, even though my name and phone number are on our reports.

When I speak with patients, I try to restrict myself to the diagnosis of the prostate cancer and to the prognostic markers that can be obtained from the biopsy specimen.

I do not claim to be an expert on the varying, and expanding, armamentarium of treatments now available.”

Wolinsky: “It is my experience that many physicians refuse to have PSA screening because they see little value in it. What do you think about the value of PSAs?”

Raff: “I do believe in PSA screening and the use of prostate biopsies. On a personal level, I lost my dad to prostate cancer, and on a professional level I have seen a real (though anecdotal — I don’t have a full data analysis) increase in high-grade prostate cancer since the decline of PSA testing. I realize PSA testing grabs a lot of men (such as you) in its net that may not need therapy, but it also finds the men who have potentially aggressive disease and will benefit from earlier therapy.”

Wolinsky: “In the same vein, many men in active surveillance programs are rebelling against biopsies because they think they can rely on multi-parameter MRIs. (My urologist, Brian Helfand, MD, PhD, is not one. He sees biopsies as essential for active surveillance, the ‘gold standard.’). What do you think?”

Raff: “My experience with MRI at this time is that it is sub-optimal, with many false positives. I cannot speak to the false negative rate — if the men don’t get biopsied, I have no way of knowing whether or not disease is present.”

Wolinsky: “We know that different pathologists may grade slides differently … but what do you do to optimize the chances that you are ‘right’ as often as possible? For example, if you have a sense of difficulty in deciding whether a particular patient has Gleason 3 + 4 or 4 + 3, can you and do you have a colleague take a look at that particular set of slides too, to get a second ‘in-house’ opinion before a report is written up? Should that be noted in the pathology report when it happens?”

Raff: “In my institution, ALL malignant cases are reviewed at a daily quality assurance committee review at a video microscope. We frequently discuss the appropriate grade on a particular slide. All our reports document that a QA review occurred. I also track the opinions of other labs when our slides are sent to other institutions for second opinion, to see if we have any institutional bias toward up or down grading.”

Wolinsky: “Have there been technological improvements in the way prostate cancer pathology is carried out that have improved the ability to ‘see’ critical histopathological information?”

Raff: “There have not been significant changes in diagnostic techniques. There have been changes in patient safety in regards to proper identification of biopsies. We initiated and published an inking technique, and DNA patient identity testing (Know Error) has been embraced by many labs.

The other significant change is in the use of molecular diagnostics for prognostic markers in prostate cancer, as well as to try to identify patients with negative biopsies who may still be at significant risk for prostate cancer.”

Wolinsky: “What do you think about the change in the ways that the pathological findings should be reported: from Gleason patterns and Gleason scores to the new ISUP (International Society of Urological Pathology) scoring system?”

Raff: “These are cosmetic changes. All are still based on pattern recognition by the diagnosing pathologist, who in turn is dependent on receiving slides from properly obtained, processed, sectioned, and stained tissue.”

Wolinsky: “Considering just prostate specimens, what would you say are the most challenging aspects of your work?”

Raff: “It takes skill to translate a two-dimensional appearance to a three-dimensional structure, ignore distractions on the slide and in the laboratory, and to recognize mimics of cancer as well as very bland appearing malignancy.”

Wolinsky: “Why is there significant variation in how different laboratories report pathological data from biopsies? Shouldn’t there be a single standard format for reporting the key data?”

Raff: “Synoptic reporting, which meets your requirements, is required for most malignant specimens. However, it is NOT mandated for prostate biopsies, leaving each lab with freedom to include those elements they see fit, with some resultant anarchy. I believe this will change over the next few years.”


last updated

Tagged with:

About author

Related Articles